CAJ | 학술논문

目的：评估曲美他嗪对心房颤动致心动过速性心肌病患者心功能的影响。方法纳入2011年1月至2013年12月心房颤动致心动过速性心肌病患者63例，随机分为对照组（n＝32）和治疗组（n＝31），对照组患者采用传统药物治疗，包括β受体阻滞剂、血管紧张素转换酶抑制剂、利尿剂、洋地黄类药物等；治疗组患者在对照组基础上联合盐酸曲美他嗪片（20 mg，3次/天）治疗，疗程为6个月。评价两组患者治疗前后左室功能[左室射血分数（LVEF）]、6分钟步行距离和N末端脑钠肽前体（NT-proBNP）水平变化。结果治疗6个月后，治疗组患者LVEF[（45.36±6.51）%]、6分钟步行距离[（512.44±180.10）m]、NT-proBNP水平[（1425.0±1275.0）ng/L]均显著改善，与对照组[（41.25±5.46）%、（435.49±116.17）m、（3150.0±2525.5）ng/L]比较差异均具有显著性（P＜0.05）。结论曲美他嗪联合常规药物可明显改善心房颤动致心动过速性心肌病患者的心脏结构和心功能，增加其运动耐量。
목적：평고곡미타진대심방전동치심동과속성심기병환자심공능적영향。방법납입2011년1월지2013년12월심방전동치심동과속성심기병환자63례，수궤분위대조조（n＝32）화치료조（n＝31），대조조환자채용전통약물치료，포괄β수체조체제、혈관긴장소전환매억제제、이뇨제、양지황류약물등；치료조환자재대조조기출상연합염산곡미타진편（20 mg，3차/천）치료，료정위6개월。평개량조환자치료전후좌실공능[좌실사혈분수（LVEF）]、6분종보행거리화N말단뇌납태전체（NT-proBNP）수평변화。결과치료6개월후，치료조환자LVEF[（45.36±6.51）%]、6분종보행거리[（512.44±180.10）m]、NT-proBNP수평[（1425.0±1275.0）ng/L]균현저개선，여대조조[（41.25±5.46）%、（435.49±116.17）m、（3150.0±2525.5）ng/L]비교차이균구유현저성（P＜0.05）。결론곡미타진연합상규약물가명현개선심방전동치심동과속성심기병환자적심장결구화심공능，증가기운동내량。
ObjectiveTo review the influence of trimetazidine on exercise tolerance of cardiac function in the patients with tachycardia cardiomyopathy.MethodThe randomized controlled trials were conducted involving 63 patients heart failure from tachycardia cardiomyopathy; they were randomly divided into control group (n=32) and test group (n=31). Patients in control group were administered with routine treatment, such as β receptor blocker, angiotensin converting enzyme inhibitor, diuretic, digitalis. The patients in test group were administered with trimetazidine (20 mg, 3 times each day) based on the routine treatment for 6 months. Left ventricular ejection fraction (LVEF), 6-minute walk test and N-terminal brain natriuretic peptide precursor (NT-proBNP) were conducted to evaluate the therapeutic effect of trimetazidine before and after treatment. ResultAfter treatment, LVEF [(45.36±6.51) %], 6-minute walk test distance [(512.44±180.10) m] and the level of NT-proBNP [(1425.0±1275.0) ng/L] in test group were better than control group [(41.25±5.46) %, (435.49±116.17) m, (3150.0±2525.5) ng/L], the difference was statistical signiifcant (P<0.05).Conclusion Trimetazidine combined with other conventional drugs can effectively improve the cardiac function of patients with heart failure from tachycardia cardiomyopathy, and increase their physical activity.